Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 5
2006 7
2007 8
2008 19
2009 9
2010 14
2011 15
2012 16
2013 18
2014 16
2015 15
2016 15
2017 18
2018 18
2019 18
2020 23
2021 16
2022 23
2023 16
2024 23
2025 22
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Antiphospholipid syndrome.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Ruiz-Irastorza G, et al. Lancet. 2010 Oct 30;376(9751):1498-509. doi: 10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6. Lancet. 2010. PMID: 20822807 Review.
Complement activation might have a central pathogenetic role. Of the different antiphospholipid antibodies, lupus anticoagulant is the strongest predictor of features related to antiphospholipid syndrome. ...Hydroxychloroquine is a potential additional treatm …
Complement activation might have a central pathogenetic role. Of the different antiphospholipid antibodies, lupus anticoagulant is th …
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease.
Salter BM, Crowther MA. Salter BM, et al. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):214-221. doi: 10.1182/hematology.2024000544. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39644034 Free PMC article. Review.
Catastrophic antiphospholipid syndrome (CAPS) is a rare but life-threatening form of antiphospholipid syndrome (APS) defined by the rapid onset of large and small vessel thrombosis occurring simultaneously across multiple sites, resulting in multiorgan …
Catastrophic antiphospholipid syndrome (CAPS) is a rare but life-threatening form of antiphospholipid syndrome ( …
Antiphospholipid Syndrome: State of the Art of Clinical Management.
Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A. Depietri L, et al. Cardiovasc Drugs Ther. 2025 Apr;39(2):385-404. doi: 10.1007/s10557-023-07496-3. Epub 2023 Aug 12. Cardiovasc Drugs Ther. 2025. PMID: 37572208 Review.
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder clinically characterized by recurrent arterial and venous thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies. ...Treatment options for the prevention of pregna …
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder clinically characterized by recurrent arterial and venous th …
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694 Free article.
Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and r …
Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered …
Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry".
Rodriguez-Pintó I, Espinosa G, Cervera R. Rodriguez-Pintó I, et al. Med Clin (Barc). 2024 Aug;163 Suppl 1:S31-S35. doi: 10.1016/j.medcli.2024.02.011. Med Clin (Barc). 2024. PMID: 39174151 Review. English, Spanish.
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). ...
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most sever …
An update on the biologics for the treatment of antiphospholipid syndrome.
Yun Z, Duan L, Liu X, Cai Q, Li C. Yun Z, et al. Front Immunol. 2023 May 19;14:1145145. doi: 10.3389/fimmu.2023.1145145. eCollection 2023. Front Immunol. 2023. PMID: 37275894 Free PMC article. Review.
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis and pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). ...Therefore, there is a need for new, targeted treatments beyond anticoag …
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis and pregnancy morbidity with the …
Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.
Okunlola AO, Ajao TO, Sabi M, Kolawole OD, Eweka OA, Karim A, Adebayo TE. Okunlola AO, et al. Cureus. 2024 Sep 19;16(9):e69730. doi: 10.7759/cureus.69730. eCollection 2024 Sep. Cureus. 2024. PMID: 39429267 Free PMC article. Review.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by blood clots and pregnancy complications due to antiphospholipid antibodies. Catastrophic APS (CAPS), a severe variant, leads to multiorgan failure and is often fatal. Pathogenesis invo …
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by blood clots and pregnancy complications due to a …
Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjogren's syndrome: evidence- and practice-based guidance.
Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, Araújo Correia J, Campar A, Brandão M, Crespo J, Marado D, Matos-Costa J, Oliveira S, Salvador F, Santos L, Silva F, Fernandes M, Vasconcelos C. Marinho A, et al. Front Immunol. 2023 Apr 17;14:1117699. doi: 10.3389/fimmu.2023.1117699. eCollection 2023. Front Immunol. 2023. PMID: 37138867 Free PMC article. Review.
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjogren's syndrome (SS) are heterogeneous autoimmune diseases. ...In these three autoimmune diseases, most recommendations refer to rituximab, which aligns with the higher number …
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjogren's syndrome (SS) are heterogeneous auto …
Use of rituximab in the antiphospholipid syndrome.
Kumar D, Roubey RA. Kumar D, et al. Curr Rheumatol Rep. 2010 Feb;12(1):40-4. doi: 10.1007/s11926-009-0074-5. Curr Rheumatol Rep. 2010. PMID: 20425532 Review.
There is increasing interest in using rituximab in other autoimmune diseases, including the antiphospholipid syndrome. We reviewed the published clinical experience of rituximab use in patients with the antiphospholipid syndrome. ...Contr …
There is increasing interest in using rituximab in other autoimmune diseases, including the antiphospholipid syndrome. …
Diagnosis and management of Evans syndrome in adults: first consensus recommendations.
Fattizzo B, Marchetti M, Michel M, Cantoni S, Frederiksen H, Giordano G, Glenthøj A, González-López TJ, Murakhovskaya I, Napolitano M, Mingot ME, Arguello M, Patriarca A, Raso S, Vianelli N, Barcellini W. Fattizzo B, et al. Lancet Haematol. 2024 Aug;11(8):e617-e628. doi: 10.1016/S2352-3026(24)00144-3. Epub 2024 Jul 2. Lancet Haematol. 2024. PMID: 38968944 Review.
Rituximab was strongly recommended as first-line treatment in cold-type AIHA and as second-line treatment in warm-type AIHA and patients with immune thrombocytopenia and antiphospholipid antibodies, previous thrombotic events, or associated lymphoproliferative disea …
Rituximab was strongly recommended as first-line treatment in cold-type AIHA and as second-line treatment in warm-type AIHA and patie …
309 results